Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder (CSP #504)

This study has been completed.
Sponsor:
Collaborator:
Janssen, LP
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00099983
First received: December 21, 2004
Last updated: August 5, 2014
Last verified: August 2014
Results First Received: August 6, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Stress Disorders
Post-Traumatic
Interventions: Drug: Risperidone
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited initially from 20 VA Medical Centers over a 2-year period. To address low recruitment rates and other issues, 8 sites were discontinued and 6 sites were added during the course of the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Risperidone

an atypical antipsychotic indicated for the treatment of schizophrenia but not for Post Traumatic Stress Disorder (PTSD). Some of additional unlabeled uses of risperidone include behavioral symptoms associated with dementia in the elderly, bipolar disorder, Tourette’s disorder, pervasive developmental disorder and autism.

(1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day).

Sugar Pill Placebo Sugar Pill 1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day).

Participant Flow:   Overall Study
    Risperidone     Sugar Pill  
STARTED     147     149  
COMPLETED     123     124  
NOT COMPLETED     24     25  
Lost to Follow-up                 2                 3  
Missing Source Documents                 14                 15  
Withdrawal by Subject                 3                 2  
Adverse Event                 1                 1  
Lack of Efficacy                 0                 1  
Unable to return for appointments                 1                 1  
Moved                 1                 0  
Other psychiatric problem                 1                 0  
Incarcerated                 0                 1  
Intolerant of burden of visits                 0                 1  
Other issue                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Valid diagnostic baseline data were collected on 267 patients randomized to receive risperidone (n=133) and placebo (n=134). The 29 patients with "missing source documents" as reported in Participant Flow were not included in any analyses.

Reporting Groups
  Description
Risperidone Risperidone : atypical antipsychotic
Sugar Pill

PTSD

Placebo : Placebo

Total Total of all reporting groups

Baseline Measures
    Risperidone     Sugar Pill     Total  
Number of Participants  
[units: participants]
  133     134     267  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     133     134     267  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  54.3  ± 10.8     54.5  ± 10.6     54.4  ± 10.7  
Gender  
[units: participants]
     
Female     5     4     9  
Male     128     130     258  
Region of Enrollment  
[units: participants]
     
United States     133     134     267  



  Outcome Measures

1.  Primary:   Change in CAPS Score From Baseline to Week 24   [ Time Frame: 24 Weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: John Krystal, MD
Organization: VA Connecticut HCS
phone: 203-937-4790
e-mail: john.krystal@yale.edu


No publications provided by Department of Veterans Affairs

Publications automatically indexed to this study:

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00099983     History of Changes
Other Study ID Numbers: 504
Study First Received: December 21, 2004
Results First Received: August 6, 2013
Last Updated: August 5, 2014
Health Authority: United States: Federal Government